Om Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.92 M
as on 16-11-2024
- Company Age 30 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 M
as on 16-11-2024
- Satisfied Charges ₹ 8.95 Cr
as on 16-11-2024
- Revenue 8.44%
(FY 2023)
- Profit -19.32%
(FY 2023)
- Ebitda -11.95%
(FY 2023)
- Net Worth 13.91%
(FY 2023)
- Total Assets 13.37%
(FY 2023)
About Om Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.92 M.
The company currently has active open charges totaling ₹4.00 M. The company has closed loans amounting to ₹8.95 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vivek Asrani, Vishal Mehra, Pravin Sonawane, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MH1994PLC082689
- Company No.
082689
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 Nov 1994
- Date of AGM
16 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Om Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Asrani  | Director | 01-Apr-2005 | Current |
| Vishal Mehra | Director | 20-Jul-2012 | Current |
| Pravin Sonawane | Director | 12-Sep-2024 | Current |
| Chetan Mansukhlal | Director | 27-Dec-2019 | Current |
Financial Performance and Corporate Structure Insights of Om Pharmaceuticals.
Om Pharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.44% increase. The company also saw a substantial fall in profitability, with a 19.32% decrease in profit. The company's net worth Soared by an impressive increase of 13.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Om Pharmaceuticals?
In 2023, Om Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Indo-Italian Furniture Company Private LimitedActive 25 years 9 monthsVivek Asrani is a mutual person
_PRIVATE_LIMITED.webp)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Sep 2024 | ₹4.00 M | Open |
Bank Of Maharashtra Creation Date: 10 Oct 2013 | ₹8.50 M | Satisfied |
Bank Of Maharashtra Creation Date: 03 Nov 2011 | ₹1.10 Cr | Satisfied |
How Many Employees Work at Om Pharmaceuticals?
Unlock and access historical data on people associated with Om Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Om Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Om Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
